TGF-β in cancer and bone: Implications for treatment of bone metastases

Patricia Juárez, Theresa Guise

Research output: Contribution to journalArticle

88 Citations (Scopus)

Abstract

Bone metastases are common in patients with advanced breast, prostate and lung cancer. Tumor cells co-opt bone cells to drive a feed-forward cycle which disrupts normal bone remodeling to result in abnormal bone destruction or formation and tumor growth in bone. Transforming growth factor-beta (TGF-β) is a major bone-derived factor, which contributes to this vicious cycle of bone metastasis. TGF-β released from bone matrix during osteoclastic resorption stimulates tumor cells to produce osteolytic factors further increasing bone resorption adjacent to the tumor cells. TGF-β also regulates 1) key components of the metastatic cascade such as epithelial-mesenchymal transition, tumor cell invasion, angiogenesis and immunosuppression as well as 2) normal bone remodeling and coupling of bone resorption and formation. Preclinical models demonstrate that blockade of TGF-β signaling is effective to treat and prevent bone metastases as well as to increase bone mass.

Original languageEnglish
Pages (from-to)23-29
Number of pages7
JournalBone
Volume48
Issue number1
DOIs
StatePublished - Jan 1 2011

Fingerprint

Bone Neoplasms
Transforming Growth Factor beta
Neoplasm Metastasis
Bone and Bones
Bone Remodeling
Neoplasms
Bone Resorption
Therapeutics
Bone Matrix
Epithelial-Mesenchymal Transition
Bone Development
Osteogenesis
Immunosuppression
Lung Neoplasms
Prostatic Neoplasms
Breast Neoplasms

Keywords

  • Bone metastasis
  • Breast cancer
  • Prostatic cancer
  • TGF-β
  • TGF-β inhibitors

ASJC Scopus subject areas

  • Physiology
  • Endocrinology, Diabetes and Metabolism
  • Histology

Cite this

TGF-β in cancer and bone : Implications for treatment of bone metastases. / Juárez, Patricia; Guise, Theresa.

In: Bone, Vol. 48, No. 1, 01.01.2011, p. 23-29.

Research output: Contribution to journalArticle

@article{31084fab45eb49f680e055d7a2a0d187,
title = "TGF-β in cancer and bone: Implications for treatment of bone metastases",
abstract = "Bone metastases are common in patients with advanced breast, prostate and lung cancer. Tumor cells co-opt bone cells to drive a feed-forward cycle which disrupts normal bone remodeling to result in abnormal bone destruction or formation and tumor growth in bone. Transforming growth factor-beta (TGF-β) is a major bone-derived factor, which contributes to this vicious cycle of bone metastasis. TGF-β released from bone matrix during osteoclastic resorption stimulates tumor cells to produce osteolytic factors further increasing bone resorption adjacent to the tumor cells. TGF-β also regulates 1) key components of the metastatic cascade such as epithelial-mesenchymal transition, tumor cell invasion, angiogenesis and immunosuppression as well as 2) normal bone remodeling and coupling of bone resorption and formation. Preclinical models demonstrate that blockade of TGF-β signaling is effective to treat and prevent bone metastases as well as to increase bone mass.",
keywords = "Bone metastasis, Breast cancer, Prostatic cancer, TGF-β, TGF-β inhibitors",
author = "Patricia Ju{\'a}rez and Theresa Guise",
year = "2011",
month = "1",
day = "1",
doi = "10.1016/j.bone.2010.08.004",
language = "English",
volume = "48",
pages = "23--29",
journal = "Bone",
issn = "8756-3282",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - TGF-β in cancer and bone

T2 - Implications for treatment of bone metastases

AU - Juárez, Patricia

AU - Guise, Theresa

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Bone metastases are common in patients with advanced breast, prostate and lung cancer. Tumor cells co-opt bone cells to drive a feed-forward cycle which disrupts normal bone remodeling to result in abnormal bone destruction or formation and tumor growth in bone. Transforming growth factor-beta (TGF-β) is a major bone-derived factor, which contributes to this vicious cycle of bone metastasis. TGF-β released from bone matrix during osteoclastic resorption stimulates tumor cells to produce osteolytic factors further increasing bone resorption adjacent to the tumor cells. TGF-β also regulates 1) key components of the metastatic cascade such as epithelial-mesenchymal transition, tumor cell invasion, angiogenesis and immunosuppression as well as 2) normal bone remodeling and coupling of bone resorption and formation. Preclinical models demonstrate that blockade of TGF-β signaling is effective to treat and prevent bone metastases as well as to increase bone mass.

AB - Bone metastases are common in patients with advanced breast, prostate and lung cancer. Tumor cells co-opt bone cells to drive a feed-forward cycle which disrupts normal bone remodeling to result in abnormal bone destruction or formation and tumor growth in bone. Transforming growth factor-beta (TGF-β) is a major bone-derived factor, which contributes to this vicious cycle of bone metastasis. TGF-β released from bone matrix during osteoclastic resorption stimulates tumor cells to produce osteolytic factors further increasing bone resorption adjacent to the tumor cells. TGF-β also regulates 1) key components of the metastatic cascade such as epithelial-mesenchymal transition, tumor cell invasion, angiogenesis and immunosuppression as well as 2) normal bone remodeling and coupling of bone resorption and formation. Preclinical models demonstrate that blockade of TGF-β signaling is effective to treat and prevent bone metastases as well as to increase bone mass.

KW - Bone metastasis

KW - Breast cancer

KW - Prostatic cancer

KW - TGF-β

KW - TGF-β inhibitors

UR - http://www.scopus.com/inward/record.url?scp=78650308466&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650308466&partnerID=8YFLogxK

U2 - 10.1016/j.bone.2010.08.004

DO - 10.1016/j.bone.2010.08.004

M3 - Article

C2 - 20699127

AN - SCOPUS:78650308466

VL - 48

SP - 23

EP - 29

JO - Bone

JF - Bone

SN - 8756-3282

IS - 1

ER -